Minfeng Chen

Minfeng Chen


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2023 in Free Radical Biology and Medicine
Verified
Journal Article
Closed access
QMQun Miao
Qun Miao
WDWei-Qing Deng
Wei-Qing Deng
WLWen-Yu Lyu
Wen-Yu Lyu
ZSZhi-Ting Sun
Zhi-Ting Sun
SFShu-Ran Fan
Shu-Ran Fan
LDLi-Juan Deng
Li-Juan Deng

4 September 2023 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
CWChenran Wang
Chenran Wang
MHMaohua Huang
Maohua Huang
YLYuning Lin
Yuning Lin
YZYiming Zhang
Yiming Zhang
JPJinghua Pan
Jinghua Pan
WYWencai Ye
Wencai Ye

1 January 2022 in Cancer Letters
Verified
Journal Article
Closed access
MHMaohua Huang
Maohua Huang
MLMingqun Liu
Mingqun Liu
DHDandan Huang
Dandan Huang
YMYanping Ma
Yanping Ma
GYGeni Ye
Geni Ye
DZDongmei Zhang
Dongmei Zhang

10 December 2019 in Cells
Verified
Journal Article
Open access
PDF file
XLXiaobo Li
Xiaobo Li
YLYong Li
Yong Li
LWlu weijin
lu weijin
MCMinfeng Chen
Minfeng Chen
WYWencai Ye
Wencai Ye
DZDongmei Zhang
Dongmei Zhang
Tumor vessels provide essential paths for tumor cells to escape from the primary tumor and form metastatic foci in distant organs. The vessel targeting strategy has been widely used as an important clinical cancer chemotherapeutic strategy for patients with metastatic tumors. Our review introduces the contribution of angiogenesis to tumor metastasis and summarizes the application of Food and Drug Administration (FDA)-approved vessel targeting drugs for metastatic tumors. We recommend the application and mechanisms of vascular targeting drugs for inhibiting tumor metastasis and discuss the risk and corresponding countermeasures after vessel targeting treatment.

27 August 2023 in Advanced Science
Verified
Journal Article
Open access
XLXiaobo Li
Xiaobo Li
QQQi Qi
Qi Qi
YLYong Li
Yong Li
QMQun Miao
Qun Miao
WYWenqian Yin
Wenqian Yin
DZDongmei Zhang
Dongmei Zhang
Hematogenous metastasis is the main approach for colorectal cancer liver metastasis (CRCLM). However, as the gatekeepers in the tumor vessels, the role of TPCs in hematogenous metastasis remains largely unknown, which may be attributed to the lack of specific biomarkers for TPC isolation. Here, microdissection combined with a pericyte medium‐based approach is developed to obtain TPCs from CRC patients. Proteomic analysis reveals that TRP channel‐associated factor 2 (TCAF2), a partner protein of the transient receptor potential cation channel subfamily M member 8 (TRPM8), is overexpressed in TPCs from patients with CRCLM. TCAF2 in TPCs is correlated with liver metastasis, short overall survival, and disease‐free survival in CRC patients. Gain‐ and loss‐of‐function experiments validate that TCAF2 in TPCs promotes tumor cell motility, epithelial‐mesenchymal transition (EMT), and CRCLM, which is attenuated in pericyte‐conditional Tcaf2‐knockout mice. Mechanistically, TCAF2 inhibits the expression and activity of TRPM8, leading to Wnt5a secretion in TPCs, which facilitates EMT via the activation of the STAT3 signaling pathway in tumor cells. Menthol, a TRPM8 agonist, significantly suppresses Wnt5a secretion in TPCs and CRCLM. This study reveals the previously unidentified pro‐metastatic effects of TPCs from the perspective of cold‐sensory receptors, providing a promising diagnostic biomarker and therapeutic target for CRCLM.

23 July 2025 in Gut
Verified
Journal Article
Open access
PDF file
SWSheng Wang
Sheng Wang
GYGeni Ye
Geni Ye
XXXiaoling Xu
Xiaoling Xu
YLYuning Lin
Yuning Lin
XLXiaobo Li
Xiaobo Li
DZDongmei Zhang
Dongmei Zhang
Background: Circulating tumour cell (CTC)-neutrophil clusters represent a key driver and a hallmark of tumour metastasis; however, efficient approaches for their elimination are still lacking. Objective: This study sought to elucidate the location and mechanisms of CTC-neutrophil cluster formation and develop more effective antimetastasis strategies. Design: Immunofluorescence staining of clinical colorectal cancer (CRC) samples was performed to identify the location of CTC-neutrophil clusters. The correlation between the expression of nicotinamide N-methyltransferase (NNMT) in pericytes and patient prognosis, as well as its association with CTC-neutrophil cluster formation, was assessed using clinical specimens and public CRC datasets. The formation process of CTC-neutrophil clusters was visualised using intravital microscope and microfluidic vascular chip models. Bulk RNA sequencing, xenograft and allograft models and pericyte-specific genetic Nnmt deficiency mice were used to investigate the effect of pericyte NNMT on CTC-neutrophil cluster formation and CRC metastasis. Results: CTC-neutrophil clusters formed at the vascular-immune interface of CRC primary tumours. Pericytes with high NNMT expression could serve as a poor prognostic biomarker that indicated an increased risk of developing metastasis in CRC. NNMT highly expressing pericytes facilitated the formation of CTC-neutrophil clusters by mediating the cellular interaction among CRC cells, neutrophils and endothelial cells through activating the CXCL5/CXCR2 axis. Genetic and pharmacological inhibition of NNMT in pericytes eliminated CTC-neutrophil clusters and suppressed CRC liver metastasis. Conclusion: This study uncovers the previously undefined location and mechanism of CTC-neutrophil cluster formation and underscores the potential of pericyte-driven CTC-neutrophil clusters as a valuable prognostic indicator and therapeutic target for CRC metastasis.